Introduction
============

No cases of vasculitis were ever reported during the pandemic 2009 H1N1 (2009 H1N1) infection, thus its occurrence can be considered rare with undetermined etiology. Systemic vasculitis has been described as an extremely rare event during influenza infection or following the administration of vaccines \[[@B1]-[@B4]\]. In addition, influenza infection has seldom been associated with various autoimmune diseases \[[@B5]\]. Among viral respiratory diseases, adenovirus and enteroviruses were previously identified in patients with the onset of rash and cutaneous vasculitis \[[@B2],[@B6]\]. Pandemic 2009 H1N1 had a broad clinical spectrum. The majority of 2009 H1N1 infections are mild and self limiting; however, since the virus can cause serious respiratory disorders in young people and lead to severe complications in non-immune people, early treatment is recommended \[[@B7]\]. In the spring of 2009, the 2009 H1N1 virus spread rapidly throughout the world. The authors describe a case of systemic vasculitis that occurred in an Australian woman suffering from 2009 H1N1 infection. She was hospitalized at the \"L. Spallanzani\" National Institute for Infectious Diseases (INMI).

Case presentation
=================

A 23-year-old Caucasian woman spending her holidays in Italy was admitted to INMI in Rome. The otherwise healthy patient presented with a two-day history of fever, severe abdominal pain, diarrhoea with bloody stools and haemorrhagic skin lesions.

Two weeks before, she had rhinorrhoea, a sore throat and a cough. She had received the first dose of human papillomavirus vaccination one month prior to her admittance. On examination, the patient looked pale, tired and feverish with a body temperature of 38.8°C. She manifested an extension of haemorrhagic purpura all over her limbs (Figure [1](#F1){ref-type="fig"}) and complained of severe abdominal pain. Nasopharyngeal and rectal swabs evidenced a 2009 H1N1 virus by reverse-transcriptase polymerase chain reaction (RT-PCR) assay. Her blood count showed mild anaemia (haemoglobin, 11.70 g/dl), neutrophilia (white blood cells 15.700/mmc: neutrophils 13.400/mmc (85.1%), lymphocytes 1.200/mmc (7,7%), monocytes 800/mmc). C-reactive protein (2.70 mg/dl) and Dimer test values (4.788 ng/dl) were elevated. Platelet count, clotting tests and ESR were normal. A urine examination showed proteinuria, red cells, leukocytes, hyaline and erythrocyte casts. Specific laboratory tests were performed ruling out immunological and autoimmune disorders, including anti-nuclear antibody profile (autoantibodies against RNP/Sm, SS-A, Ro-52, SS-B, Scl-70, Jo-1, centromere B, dsDNA, histones, anti-mitochondrial M2 antibody), anti-smooth muscle, anti-liver-kidney microsomal antibodies, anti-platelets, anti-gastric parietal cell, anti-cardiolipin IgG and IgM, anti-neutrophilic cytoplasmic antibodies (ANCA), lupus anticoagulant, rheumatoid factor (RF), and Coombs test. Serological tests ruled out acute bacterial or viral infections including *Brucella*species, *Salmonella*species, *Rickettsia conori*, *Coxiella burneti*or viruses such as dengue, cytomegalovirus, Epstein-Barr virus, herpes simplex, HIV, coxsackievirus, echovirus and adenovirus. Bacterial nasopharyngeal, blood and urine cultures were sterile. Chest and abdomen X-rays were normal. A computed tomography (CT)-scan of her abdomen and pelvis without contrast revealed only a small effusion in the pouch of Douglas. Oseltamivir (75 mg twice a day, orally) and ciprofloxacin (400 mg twice a day, intravenously) were administered. A short course of methylprednisolone was administered intravenously, starting at 40 mg on July 15 and then reduced by 10 mg daily until it was withdrawn on July 20. Her clinical condition improved during hospitalization. By Day three the leukocytosis decreased (white blood cells 10.100/mmc, neutrophils 5.600/mmc, lymphocytes 3600/mmc). The fever disappeared in three days, her abdominal pain was resolved and there was a marked improvement in the vasculitic lesions. On Day seven she chose to leave the hospital against medical advice.

![**Overview of the features of purpura before treatment**. **A, C:** show an overview of the features of purpura before treatment. **B**: details the hemorrhagic-necrotic skin lesions on the feet, associated with petechial lesions on the lateral part of the right foot.](1752-1947-5-132-1){#F1}

Discussion
==========

The rash that can occur during influenza virus infection usually has a macular or maculopapular aspect and can be confused with measles. Hope-Simpson and Higgins \[[@B8]\] found that approximately 8% of influenza B infections and 2% of influenza A virus infections are associated with rash. In addition, Silva and others \[[@B1]\] described a case of a child with a febrile petechial rash associated with influenza A virus infection.

Although cases of vasculitis have occurred following influenza vaccination \[[@B3],[@B4]\], to our knowledge there are no reports concerning cases of systemic vasculitis associated with the 2009 H1N1 infection. An immune thrombocytopenic purpura following human papillomavirus vaccination has been reported \[[@B9]\]. Other vasculitic conditions and sepsis were excluded.

The etiology of Henoch-Schönlein purpura (HSP), which is a systemic vasculitis described mainly in childhood (0.013 to 0.02%), actually remains unknown \[[@B10]\]. In our case, the skin and abdominal haemorrhagic manifestations associated with a normal platelet count could be related to both the 2009 H1N1 infection and HSP. Streptococcal, *Mycoplasma*species, adenovirus, parvovirus and coxsackievirus infections have been reported to precede HSP \[[@B10]\]. In our case, an upper respiratory tract infection occurred first. The main diagnostic hallmarks of HSP include clinical and histological features. In this case the clinical features of HSP such as fever, purpuric rash, bloody stools, hematuria, abdominal pain, joints and kidney involvement, and normal platelet count were present. We did not perform a biopsy of the skin lesions because of the voluntary discharge of the patient.

Vasculitis may result from the interaction between influenza virus antigen A H1N1 and the host\'s immune response. It has been hypothesized as being a pathogenetic immune-mediated mechanism induced by infections \[[@B10],[@B11]\]. Deregulation of cytokine biosynthesis has been considered the fundamental pathogenetic mechanism related to the severity and progression of 2009 H1N1 influenza \[[@B12]\]. Particularly, the secretion of Th1 and Th17 cytokines was reported as an early host response in severe 2009 H1N1 infection \[[@B13]\] and it is well known that these cytokines are also involved in inflammatory and autoimmune responses \[[@B14]\]. The pro-inflammatory immune response may facilitate the occurrence of vasculitis during a severe pandemic infection.

The spectrum of treatment against vasculitis during influenza infection has been broadly discussed. Steroid therapy was not absolutely contraindicated during 2009 H1N1 infection as reported in the scientific literature. Quispe-Laime and others reported that in patients with H1N1 influenza affected by severe respiratory complications, treatment with a prolonged, moderate dose of corticosteroids was associated with significant improvement in lung injury, multiple organ function scores and low hospital mortality \[[@B15]\]. Carter MJ *et al.*argued that steroids can have an additional role to antiviral therapy in the treatment of severe cases of H5N1 avian flu \[[@B13]\]. In our case, on the basis of a high clinical suspicion of severe vasculitis syndrome and considering the rapid impairment of the clinical conditions, a short-course of steroid therapy was added to the antiviral drugs. Despite the steroid therapy, by Day 6 the nasopharyngeal swab did not show evidence of the presence of 2009 H1N1 virus by RT-PCR. Randomized clinical trials are needed to determine whether additional steroid treatment could be beneficial to dominate spreading of the cytokines, which occurs in severe pandemic H1N1 influenza.

Conclusion
==========

Systemic vasculitis associated with 2009 H1N1 infection is extremely rare. In this case, the role of the 2009 H1N1 influenza virus in the pathogenesis of hemorrhagic manifestations should be considered. The lack of a histopathological study of the skin lesions may limit our conclusions; however, the macroscopic characteristics of the purpura suggest a vasculitic process. Overall, the clinical, immunological and radiological features are consistent with the clinical diagnosis of HSP. In our case, a short course of steroid therapy in addition to antivirals did not delay the clearance of 2009 H1N1 virus and the combined treatment contributed to improving a complicated case of vasculitis.
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